Format

Send to

Choose Destination
AIDS. 2016 Jul 17;30(11):1849-52. doi: 10.1097/QAD.0000000000001140.

Comparison of efavirenz and protease inhibitor based combination antiretroviral therapy regimens in treatment-naïve people living with HIV with baseline resistance.

Author information

1
aImperial College London, South Kensington CampusbChelsea and Westminster Hospital NHS Foundation TrustcBarts Healthcare NHS Trust, London, UK.

Abstract

A retrospective cohort analysis comparing the efficacy of boosted protease inhibitor-based and efavirenz-based combination antiretroviral therapy in treatment-naïve people living with HIV with baseline resistance found that efavirenz-based treatment led to a shorter mean time to undetectable viral load. A higher proportion of patients with nonnucleoside reverse transcriptase inhibitor related baseline resistance mutations in the efavirenz-treatment group achieved an undetectable viral load at both 6 and 12 months post-treatment initiation, compared with the boosted protease-inhibitor-treatment group.Supplementary content: http://links.lww.com/QAD/A930.

PMID:
27139315
DOI:
10.1097/QAD.0000000000001140
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center